These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 12457619)
1. Pharmacological and biological aspects of basic research on nucleoside-based reverse transcriptase inhibitors. Macchi B; Mastino A Pharmacol Res; 2002 Dec; 46(6):473-82. PubMed ID: 12457619 [TBL] [Abstract][Full Text] [Related]
2. Structure, Synthesis and Inhibition Mechanism of Nucleoside Analogues as HIV-1 Reverse Transcriptase Inhibitors (NRTIs). Yoshida Y; Honma M; Kimura Y; Abe H ChemMedChem; 2021 Mar; 16(5):743-766. PubMed ID: 33230979 [TBL] [Abstract][Full Text] [Related]
3. [Mechanisms of HIV-1 drug resistance to nucleoside and non-nucleoside reverse transcriptase inhibitors]. Nikolenko GN; Kotelkin AT; Oreshkova SF; Il'ichev AA Mol Biol (Mosk); 2011; 45(1):108-26. PubMed ID: 21485502 [TBL] [Abstract][Full Text] [Related]
4. Biochemical and mechanistic basis for the activity of nucleoside analogue inhibitors of HIV reverse transcriptase. Painter GR; Almond MR; Mao S; Liotta DC Curr Top Med Chem; 2004; 4(10):1035-44. PubMed ID: 15193137 [TBL] [Abstract][Full Text] [Related]
5. Nucleoside and nucleotide inhibitors of HIV-1 replication. Vivet-Boudou V; Didierjean J; Isel C; Marquet R Cell Mol Life Sci; 2006 Jan; 63(2):163-86. PubMed ID: 16389458 [TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs). Sluis-Cremer N; Arion D; Parniak MA Cell Mol Life Sci; 2000 Sep; 57(10):1408-22. PubMed ID: 11078020 [TBL] [Abstract][Full Text] [Related]
7. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Sharma PL; Nurpeisov V; Hernandez-Santiago B; Beltran T; Schinazi RF Curr Top Med Chem; 2004; 4(9):895-919. PubMed ID: 15134548 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals. Imaz A; Llibre JM; Mora M; Mateo G; Camacho A; Blanco JR; Curran A; Santos JR; Caballero E; Bravo I; Gayá F; Domingo P; Rivero A; Falcó V; Clotet B; Ribera E J Antimicrob Chemother; 2011 Feb; 66(2):358-62. PubMed ID: 21172789 [TBL] [Abstract][Full Text] [Related]
9. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure. Miller V; Larder BA Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471 [TBL] [Abstract][Full Text] [Related]
13. The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS). De Clercq E Adv Pharmacol; 2013; 67():317-58. PubMed ID: 23886005 [TBL] [Abstract][Full Text] [Related]
14. [Clinical pharmacology of nucleoside and nucleotide reverse transcriptase inhibitors]. Bonora S; Calcagno A; Gonzalez de Requena D; Bargiacchi O; Di Perri G Infez Med; 2006 Jun; 14(2):61-70. PubMed ID: 16891850 [TBL] [Abstract][Full Text] [Related]
16. A brief overview of mechanisms of mitochondrial toxicity from NRTIs. Kohler JJ; Lewis W Environ Mol Mutagen; 2007; 48(3-4):166-72. PubMed ID: 16758472 [TBL] [Abstract][Full Text] [Related]
17. Essential benefits of nucleoside analogue regimens in failing therapy. Geretti AM J HIV Ther; 2004 May; 9(2):28-33. PubMed ID: 15238873 [TBL] [Abstract][Full Text] [Related]
18. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Cihlar T; Ray AS Antiviral Res; 2010 Jan; 85(1):39-58. PubMed ID: 19887088 [TBL] [Abstract][Full Text] [Related]
19. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future. De Clercq E Chem Biodivers; 2004 Jan; 1(1):44-64. PubMed ID: 17191775 [TBL] [Abstract][Full Text] [Related]
20. A Review on the New Indication of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in the Treatment of Coronavirus Disease 2019. Karbasforooshan H; Salari S; Hosseinjani H Infect Disord Drug Targets; 2022; 22(5):e180222201281. PubMed ID: 35184718 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]